W.A.T. and A.F. contributed equally to this work
Early Detection and Diagnosis
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe†
Version of Record online: 24 JUL 2012
Copyright © 2012 UICC
International Journal of Cancer
Volume 132, Issue 4, pages 854–867, 15 February 2013
How to Cite
Tjalma, W. A., Fiander, A., Reich, O., Powell, N., Nowakowski, A. M., Kirschner, B., Koiss, R., O'Leary, J., Joura, E. A., Rosenlund, M., Colau, B., Schledermann, D., Kukk, K., Damaskou, V., Repanti, M., Vladareanu, R., Kolomiets, L., Savicheva, A., Shipitsyna, E., Ordi, J., Molijn, A., Quint, W., Raillard, A., Rosillon, D., De Souza, S. C., Jenkins, D., Holl, K. and for the HERACLES/SCALE Study Group (2013), Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer, 132: 854–867. doi: 10.1002/ijc.27713
Conflicts of Interest: W.A. Tjalma has received support for travel to meetings for the study or other purposes from GSK, Merck and Sanofi Pasteur. A. Fiander has been on advisory boards for both GSK and Sanofi Pasteur MSD and received research grant funding and support to attend HPV-related conferences from both companies. N. Powell's laboratory has received funding from GSK, including for the work in support of this study; he has received honoraria from GSK and Sanofi Pasteur to speak/advise on HPV and has also received support for travel to study-related meetings. A.M. Nowakowski and his institution have been paid by GSK for participation in the study, and he has received support for travel to study-related meetings; he has also been paid by GSK and MSD for lectures. B. Kirschner has received support from GSK for travel and is a paid consultant to GSK's Advisory Board on vaccine-related issues. J. O'Leary, V. Damaskou, M. Repanti and their institutions received funding from GSK to complete the work disclosed in this publication. E.A. Joura and his institution have received grants from GSK and Merck for HPV vaccine studies; he is also a paid member of the board of Merck (HPV vaccines), has received travel expenses from Merck, Sanofi Pasteur MSD and GSK and has also been paid by GSK, Merck and Sanofi Pasteur MSD for lectures. M. Rosenlund was employed by GSK Biologicals at the time of study; B. Colau, K. Holl and D. Rosillon are employed by GSK Biologicals; B. Colau and M. Rosenlund also have stock or stock options in GSK Biologicals. D. Schledermann has received support from GSK for congress registration and travel. A. Savicheva and E. Shipitsyna have received consulting fees or honoraria for their participation in the study and travel expenses and have previously participated in a HPV vaccine trial for GSK. The employer of A. Molijn and W. Quint, DDL Diagnostic Laboratories, has received support from GSK for travel to meetings for the study or other purposes, fees for participation in review activities such as data monitoring boards, statistical analysis and end-point committees and also grants and fees for consultancy outside the submitted work. The employer of S. Collas De Souza and A. Raillard, 4Clinics, has received consulting fees from GSK for statistical analysis. D. Jenkins was, at the time of this study, initially an employee and then consultant in HPV to GSK Biologicals. O. Reich, R. Koiss, K. Kukk, R. Vladareanu, L. Kolomiets and J. Ordi declare no conflicts of interest. Role of the funding source: The costs related to the collection of tissue and the analysis of data from both studies, together with the development of this article, were funded and coordinated by GlaxoSmithKline Biologicals.
- Issue online: 19 DEC 2012
- Version of Record online: 24 JUL 2012
- Accepted manuscript online: 3 JUL 2012 01:28AM EST
- Manuscript Accepted: 30 MAR 2012
- Manuscript Received: 22 AUG 2011
- GlaxoSmithKline Biologicals
- 1IARC. Globocan 2008, Section of Cancer Information. Available at: http://globocan.iarc.fr/factsheets/cancers/cervix.asp. Accessed on February 17, 2011.
- 2WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Europe. Summary Report 2010. Available at: www.who.int/hpvcentre. Accessed on February 1, 2011.
- 19World Health Organization: tumours of the breast and female genital organs (WHO/IARC classification of tumours; WHO classification of tumours). Lyon: IARC Press, 2003., .
- 21Kendall's advanced theory of statistics, 6th edn. London: Edward Arnold, 1994., .